Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management

Seminars in Hematology

Volumn 44, Issue 3, 2007, Pages 157-165

  Beutel, Gernot ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER; CANCER THERAPY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED PRACTICE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOEMBOLISM;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES; SURVIVAL ANALYSIS;

EID: 34447095903     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.04.004     Document Type: Article

References (73)

1. Ludwig H., Van B.S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
2. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91 (1999) 1616-1634
3. Knight K., Wade S., and Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 116 suppl 7A (2004) 11S-26S
4. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 354 (2006) 2034-2045
5. Wood P.A., and Hrushesky W.J. Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest 95 (1995) 1650-1659
6. Ludwig H., and Strasser K. Symptomatology of anemia. Semin Oncol 28 (2001) 7-14
7. Vogelzang N.J., Breitbart W., Cella D., Curt G.A., Groopman J.E., Horning S.J., et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (1997) 4-12
8. Lind M., Vernon C., Cruickshank D., Wilkinson P., Littlewood T., Stuart N., et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86 (2002) 1243-1249
9. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (1997) 13-19
10. Ahlberg K., Ekman T., Gaston-Johansson F., and Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 362 (2003) 640-650
11. Goodnough L.T. Risks of blood transfusion. Anesthesiol Clin North America 23 (2005) 241-252
12. Toy P., Popovsky M.A., Abraham E., Ambruso D.R., Holness L.G., Kopko P.M., et al. Transfusion-related acute lung injury: Definition and review. Crit Care Med 33 (2005) 721-726
13. Blajchman M.A., and Hebert P.C. Red blood cell transfusion strategies. Transfus Clin Biol 8 (2001) 207-210
14. Hebert P.C., Wells G., Blajchman M.A., Marshall J., Martin C., Pagliarello G., et al., Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340 (1999) 409-417
15. Simon T.L., Alverson D.C., AuBuchon J., Cooper E.S., DeChristopher P.J., Glenn G.C., et al. Practice parameter for the use of red blood cell transfusions: Developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. Arch Pathol Lab Med 122 (1998) 130-138
16. Murphy M.F., Wallington T.B., Kelsey P., Boulton F., Bruce M., Cohen H., et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol 113 (2001) 24-31
17. D'Andrea A.D., Lodish H.F., and Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell 57 (1989) 277-285
18. Koury M.J., and Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248 (1990) 378-381
19. Lai P.H., Everett R., Wang F.F., Arakawa T., and Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem 261 (1986) 3116-3121
20. Koury S.T., Bondurant M.C., and Koury M.J. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71 (1988) 524-527
21. Koury S.T., Bondurant M.C., Koury M.J., and Semenza G.L. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77 (1991) 2497-2503
22. Macdougall I.C. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4 (2005) 436-440
23. Goldwasser E., Kung C.K., and Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 249 (1974) 4202-4206
24. Egrie J.C., Dwyer E., Browne J.K., Hitz A., and Lykos M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31 (2003) 290-299
25. Waltzman R., Croot C., Justice G.R., Fesen M.R., Charu V., and Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 10 (2005) 642-650
26. Morreale A., Plowman B., DeLattre M., Boggie D., and Schaefer M. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 20 (2004) 381-395
27. Cazzola M., Beguin Y., Kloczko J., Spicka I., and Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122 (2003) 386-393
28. Procrit (epoetin alfa) full prescribing information: http://www.orthobiotech.com/common/prescribing_information/PROCRIT/PDF/ProcritBooklet.pdf. Accessed March 1, 2007
29. Aranesp (darbepoetin alfa) prescribing information: http://www.aranesp.com/pdf/aranesp_PI.pdf; accessed May 6, 2007
30. NeoRecormon (epoetin beta) Roche UK package leafeat: http://www.rocheuk.com/productdb/documents/rx/pil/neorecormon_pfs_pil.pdf; accessed January 1, 2007
31. Glaspy J., Vadhan-Raj S., Patel R., Bosserman L., Hu E., Lloyd R.E., et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol 24 (2006) 2290-2297
32. Storring P.L., Tiplady R.J., Gaines Das R.E., Stenning B.E., Lamikanra A., Rafferty B., et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100 (1998) 79-89
33. Kwan J.T., Pratt R.D., and Epoetin Delta Study Group. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 23 (2007) 307-311
34. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidefeld J., Bennett C.L., Cella D., et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100 (2002) 2303-2320
35. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 (2007) 258-270
36. NCCN Clinical Practice Guidelines in Oncology v.2.2007: Cancer- and Treatment-Related Anemia. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf; accessed May 6, 2007
37. Quirt I, Bramwell V, Charette M, Oliver T, Systemic Treatment Disease Site Group: The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. http://www.cancercare.on.ca/pdf/pebc12-1f.pdf; accessed May 6, 2007
38. Seidenfeld J., Piper M., Flamm C., Hasselblad V., Armitage J.O., Bennett C.L., et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93 (2001) 1204-1214
39. Bottomley A., Thomas R., Van S.K., Flechtner H., and Djulbegovic B. Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about?. Lancet Oncol 3 (2002) 145-153
40. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3 (2006) CD003407
41. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
42. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J., et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
43. Clark O., Adams J.R., Bennett C.L., and Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2 (2002) 23
44. Bohlius J., Langensiepen S., Schwarzer G., Seidenfeld J., Piper M., Bennet C., et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev (2004) CD003407
45. Smith K.J., Bleyer A.J., Little W.C., and Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc Res 59 (2003) 538-548
46. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
47. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 (2003) 459-460
48. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
49. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
50. DAHANCA: Danish Head and Neck Cancer Group. http://frejacms.au.dk/dahanca/get_media_file.php?mediaid=125; accessed May 7, 2007
51. FDA Safety Information and Adverse Event Reporting Program: 2007 Safety Alert: Aranesp (darbepoetin alfa). http://www.fda.gov/Medwatch/safety/2007/Aranesp_DHCP_012707.htm; accessed May 6, 2007
52. Wright J.R., Ung Y.C., Julian J.A., Pritchard K.I., Whelan T.J., Smith C., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
53. FDA Information for Healthcare Professionals: Information in Erythopoiesis Stimulating Agents (ESA) (market as Procrit, Epogen, and Aranesp) 11/16/2006, Updated 2/16/2007 and 3/9/2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm; accessed March 9, 2007
54. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
55. Rossert J., Casadevall N., and Eckardt K.U. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15 (2004) 398-406
56. Locatelli F., and Del V.L. Pure red cell aplasia secondary to treatment with erythropoietin. J Nephrol 16 (2003) 461-466
57. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346 (2002) 469-475
58. Eckardt K.U., and Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18 (2003) 865-869
59. Peces R., de la Torre M., Alcazar R., and Urra J.M. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335 (1996) 523-524
60. Gershon S.K., Luksenburg H., Cote T.R., and Braun M.M. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 346 (2002) 1584-1586
61. Verhelst D., Rossert J., Casadevall N., Kruger A., Eckardt K.U., and Macdougall I.C. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet 363 (2004) 1768-1771
62. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24 (2002) 1720-1740
63. Bennett C.L., Luminari S., Nissenson A.R., Tallman M.S., Klinge S.A., McWilliams N., et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351 (2004) 1403-1408
64. Heuser M., and Ganser A. Recombinant human erythropoietin in the treatment of nonrenal anemia. Ann Hematol 85 (2006) 69-78
65. Ludwig H., Fritz E., Leitgeb C., Pecherstorfer M., Samonigg H., and Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84 (1994) 1056-1063
66. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91 (2001) 2214-2221
67. Vaupel P., and Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 12 (2005) 5-10
68. Hockel M., Knoop C., Schlenger K., Vorndran B., Baussmann E., Mitze M., et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26 (1993) 45-50
69. Kelleher D.K., Mattheinsen U., Thews O., and Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56 (1996) 4728-4734
70. Thews O., Koenig R., Kelleher D.K., Kutzner J., and Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78 (1998) 752-756
71. Silver D.F., and Piver M.S. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 73 (1999) 280-284
72. Thews O., Kelleher D.K., and Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61 (2001) 1358-1361
73. Stuben G., Pottgen C., Knuhmann K., Schmidt K., Stuschke M., Thews O., et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 55 (2003) 1358-1362